Macular Telangiectasia Type 2: Protecting Your Central Vision
Understanding Macular Telangiectasia Type 2
Macular telangiectasia type 2 is a disease that affects the macula, the small central area of the retina responsible for sharp, detailed vision. The condition involves changes to the tiny blood vessels around the fovea, which is the very center of the macula. These blood vessels may widen and become abnormal over time.
Although it was once thought to be primarily a blood vessel disease, researchers now understand that MacTel type 2 is largely a neurodegenerative condition. This means it involves the gradual loss of specialized cells in the retina, particularly Muller cells, which play a key role in supporting retinal health. The loss of these cells contributes to thinning and scarring of macular tissue.
As the disease progresses, the abnormal blood vessels around the fovea may leak fluid or blood. In some cases, new blood vessels form beneath the retina, a complication called macular neovascularization. Fluid from these leaking vessels causes the macula to swell or thicken, which blurs central vision.
Over time, tissue in the macula and fovea may thin out or develop scar tissue. This scarring leads to a loss of fine detail vision. MacTel type 2 does not affect side vision and does not typically cause total blindness. However, the loss of central vision progresses over a period of 10 to 20 years and can significantly affect daily activities such as reading and driving.
MacTel type 2 is sometimes confused with age-related macular degeneration or diabetic macular edema because all three conditions involve the macula. However, MacTel type 2 has a distinct cause rooted in Muller cell degeneration rather than the drusen deposits seen in macular degeneration. The pattern of blood vessel changes and the way the retina thins on imaging tests help a retina specialist distinguish MacTel type 2 from other conditions.
Who Is Affected and Risk Factors
MacTel type 2 most often appears in middle-aged adults, typically affecting people over the age of 40. Both men and women develop the condition. Some research suggests a slight predilection for women, though both sexes are affected in meaningful numbers.
The prevalence of MacTel type 2 has long been underestimated. Studies suggest it may affect as many as 0.1% of people aged 40 and older (Progress in Retinal and Eye Research, 2013). The Beaver Dam Eye Study of 4,790 people aged 43 to 86 years found MacTel type 2 was present in 0.1% of the study population (Beaver Dam Eye Study, PMC, 2010). Because early stages often produce no symptoms, many cases likely go undiagnosed.
Certain systemic health conditions may increase the risk of developing MacTel type 2. Up to 45% of patients with MacTel have a systemic disorder. The most common associated conditions include:
- Diabetes
- Hypertension (high blood pressure)
- Obesity
- Cardiovascular disease
MacTel type 2 affects both eyes, but it does not progress at the same rate in each eye. One eye may show more advanced changes while the other remains in an earlier stage. This asymmetry can make the condition harder to notice in its early phases because the less affected eye may compensate for the other.
Signs and Symptoms
In the early stages, people with MacTel type 2 typically have no noticeable symptoms. The condition may only be detected during a routine dilated eye examination. Because the disease develops slowly, subtle changes to vision can go unnoticed for years.
As the disease advances, several symptoms may appear. These develop gradually over months or years and include:
- Blurring of central vision
- Distorted vision, where straight lines may appear wavy or bent
- Difficulty reading or seeing fine details
- A need for brighter light when reading or performing close-up tasks
- A gradual loss of central vision in one or both eyes
If new abnormal blood vessels form beneath the retina, symptoms may change more noticeably. Leaking or bleeding from these vessels can cause a sudden worsening of central vision or a new area of blurriness. If you experience a sudden change in vision, see a retina specialist or go to the emergency room promptly. While MacTel type 2 is generally a slow condition, neovascular complications require timely evaluation.
Diagnosis and Testing
A retina specialist can detect MacTel type 2 during a comprehensive dilated eye examination. By looking at the retina with specialized instruments, the specialist may observe characteristic changes around the fovea. These can include a circular reddish spot at the fovea, crystalline deposits scattered in the retina, and pigment clumping near the macula.
Optical coherence tomography, or OCT, is a key imaging test for diagnosing and monitoring MacTel type 2. This noninvasive scan creates detailed cross-sectional images of the retina. In MacTel type 2, OCT typically reveals thinning of the retinal tissue in the macula, small cavities within the retina, and loss of photoreceptors (the light-sensing cells). These OCT findings are central to confirming the diagnosis and have helped researchers understand the neurodegenerative nature of the disease.
Fluorescein angiography is another test that a retina specialist may use. In this procedure, a special dye is injected into a vein in the arm. As the dye travels through the blood vessels of the retina, a camera captures images showing areas of leakage and abnormal blood vessels. This test helps identify whether neovascularization has developed and how much the blood vessels are leaking.
OCT angiography, or OCTA, is a newer imaging method that maps blood flow in the retina without the need for dye injection. It can detect subtle changes in the tiny blood vessels around the fovea and identify early neovascularization. OCTA is increasingly used alongside standard OCT to provide a more complete picture of the disease.
Treatment Options
In March 2025, the FDA approved revakinagene taroretcel-lwey (ENCELTO), making it the first and only FDA-approved treatment for adults with MacTel type 2. ENCELTO is an encapsulated cell-based gene therapy. It consists of a small capsule, about the size of a grain of rice, that is surgically placed inside the eye by a retina specialist.
The capsule contains living cells that have been genetically modified to continuously produce and release a protein called recombinant human ciliary neurotrophic factor, or rhCNTF. This protein reaches the retina directly and helps protect the health of retinal cells. Specifically, it supports Muller cells and photoreceptors, slowing the loss of these critical light-sensing cells.
Clinical trials demonstrated that ENCELTO significantly slowed the loss of macular photoreceptors over 24 months. In Protocol A of the trials, treated patients experienced a 56.4% reduction in photoreceptor loss compared to untreated patients (Neurotech Pharmaceuticals, 2025). Protocol B showed a 29.2% reduction in photoreceptor loss (Neurotech Pharmaceuticals, 2025). ENCELTO is expected to be available in the United States for patients starting in mid-2025.
When MacTel type 2 progresses to develop neovascularization, anti-VEGF (vascular endothelial growth factor) injections may be recommended. Anti-VEGF medicines block a chemical that drives the growth of abnormal blood vessels beneath the retina. These injections reduce the growth of new vessels, slow leakage, and help decrease macular swelling.
Avastin (bevacizumab), which is FDA-approved for cancer and used off-label for eye conditions, has been studied in proliferative MacTel type 2. Research has shown that Avastin can cause the abnormal new vessels to shrink and may improve visual acuity. It may also lead to a decrease in leakage and retinal thickness. Other anti-VEGF agents such as Eylea (aflibercept) or Lucentis (ranibizumab) may also be considered depending on the clinical situation.
In the early stages of MacTel type 2, particularly before the availability of ENCELTO, many patients were monitored with regular eye exams and imaging rather than treated. A retina specialist may still recommend a period of close observation for patients with very early disease to track the rate of progression before deciding on treatment. Regular OCT scans are essential to detect any changes that may require intervention.
What to Expect
MacTel type 2 is a slowly progressive condition. Central vision loss typically develops over 10 to 20 years. The rate of progression varies between individuals and between the two eyes. Some people maintain functional vision for many years, while others may experience more noticeable decline. With the approval of ENCELTO, there is now a way to slow the loss of photoreceptors and potentially preserve vision longer.
The ENCELTO capsule is placed inside the eye during a surgical procedure performed by a retina specialist. Because the capsule is designed to continuously release rhCNTF, it provides ongoing treatment without the need for repeated injections. Your retina specialist will schedule follow-up visits to monitor the implant and assess how the retina is responding. As with any eye surgery, there are risks that your specialist will discuss before the procedure.
If anti-VEGF injections are needed for neovascular complications, you can expect a series of treatments. Avastin (bevacizumab), which is used off-label for this indication, is typically given every four to six weeks. Other anti-VEGF agents have varying treatment intervals. The injections are performed in the office. Most people experience mild discomfort rather than significant pain. Your retina specialist will monitor your response with regular imaging and adjust the treatment schedule as needed.
Living with Macular Telangiectasia Type 2
Because MacTel type 2 affects central vision but spares side vision, many people continue to function well in their daily lives, especially in the earlier stages. Several strategies can help maximize remaining vision:
- Use bright, directed lighting for reading and close-up work
- Try large-print books, magazines, or e-readers with adjustable font size
- Use magnifying devices recommended by a low vision specialist
- Position reading material or screens to take advantage of areas of clearer vision
Because diabetes, hypertension, obesity, and cardiovascular disease are commonly associated with MacTel type 2, managing these conditions is an important part of overall care. Keeping blood sugar levels, blood pressure, and weight within healthy ranges may support general eye health. Work with your primary care doctor or other specialists to manage these conditions effectively.
A gradual loss of central vision can affect your independence and emotional well-being. Low vision rehabilitation services can help you learn new techniques for everyday tasks. Support groups for people with macular conditions can provide encouragement and practical advice from others who share similar experiences. Do not hesitate to ask your retina specialist about referrals to low vision services.
When to See a Retina Specialist
If you are over 40, especially if you have diabetes, hypertension, or a family history of macular disease, regular dilated eye exams are important. Because MacTel type 2 causes no symptoms in its early stages, only a thorough examination can detect it early. Early detection allows for closer monitoring and timely treatment decisions.
Contact a retina specialist promptly if you notice any of the following changes in your vision:
- New or worsening blurriness in your central vision
- Distortion where straight lines appear wavy
- Difficulty reading even with adequate lighting
- A dark or blank spot in the center of your vision
If you experience sudden vision loss, a sudden increase in floaters, or flashes of light, see a retina specialist or go to the emergency room immediately. While these symptoms may not be related to MacTel, they can indicate other serious retinal conditions that need urgent care.
Questions and Answers
Yes. MacTel type 2 can be identified through a dilated eye exam and OCT imaging before you notice any vision changes. Because the disease causes no symptoms in its early stages, routine eye exams are the most reliable way to catch it early. If you are over 40 or have risk factors such as diabetes or hypertension, regular screening is especially important.
ENCELTO is designed to slow the loss of photoreceptors in the macula, not to restore vision that has already been lost. Clinical trials showed it significantly reduced the rate of photoreceptor loss over 24 months. Starting treatment earlier in the disease course, before significant cell loss has occurred, may help preserve more vision over time. Your retina specialist can help determine whether ENCELTO is appropriate for your stage of the disease.
MacTel type 2 does not typically cause total blindness. The condition affects central vision, which is used for tasks like reading, recognizing faces, and driving. Side vision, also called peripheral vision, is preserved. While central vision loss can be significant and affect daily activities, most people retain enough peripheral vision to navigate their surroundings.
No. Although both conditions affect the macula and can cause central vision loss, they are distinct diseases with different causes. MacTel type 2 involves degeneration of Muller cells and changes to the small blood vessels at the fovea. Age-related macular degeneration involves drusen deposits and different patterns of cell damage. The treatments for each condition differ as well. A retina specialist can perform the testing needed to make an accurate diagnosis.
The frequency of follow-up visits depends on the stage of your disease and whether you are receiving treatment. In the monitoring phase, a retina specialist may schedule visits every three to six months for OCT imaging. After ENCELTO implant placement, more frequent visits may be needed initially to check the implant and retinal response. If you are receiving anti-VEGF injections for neovascularization, visits may occur every four to eight weeks. Your retina specialist will create a schedule tailored to your specific needs.